The company granted stock options to purchase an aggregate of 79,950 shares of Nurix common stock and restricted stock unit ...

Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates.

Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates.

NRIX stock opened at $9.14 on Wednesday. Nurix Therapeutics has a 1 year low of $8.18 and a 1 year high of $29.56. The company’s 50-day moving average is $14.03 and its 200-day moving average is ...

Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $29.56. The firm has a market cap of $671.64 million, a PE ratio of -3.05 and a beta of 2.23.

UBS lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $35 and keeps a Buy rating on the shares. Lead program bexobrutideg, a bruton tyrosine kinase degrader, continues ...

Revenue: US$18.5m (up 11% from 1Q 2024). Net loss: US$56.4m (loss widened by 36% from 1Q 2024). US$0.67 loss per share. We've found 21 US stocks that are forecast to pay a dividend yield of over 6 ...